All the risks taken by Serum Institute have finally paid off, tweeted Adar Poonawalla, the chief executive of the Pune-based vaccine manufacturer, shortly after the country's drug regulator cleared its Covishield vaccine for emergency approval in India. Mr Poonawalla said that the "Covishield" vaccine -- developed by Serum Institute of India in partnership with the Oxford University and pharma major AstraZeneca - "is now ready to roll out in the coming weeks".
Happy new year, everyone! All the risks @SerumInstIndia took with stockpiling the vaccine, have finally paid off. COVISHIELD, India's first COVID-19 vaccine is approved, safe, effective and ready to roll-out in the coming weeks. pic.twitter.com/TcKh4bZIKK- Adar Poonawalla (@adarpoonawalla) January 3, 2021
Apart from Covishield, Bharat Biotech's Covaxin has been granted permission for "restricted use".
The Drug Controller General of India VG Somani said both firms submitted data on their trial runs and both have been granted permission for "restricted use".